Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2169938 | Current Opinion in Cell Biology | 2009 | 12 Pages |
Abstract
Intervention in protein kinase C (PKC) has a chequered history, partly because of the poor selectivity of many inhibitors and partly a reflection of the sometimes antagonistic action of related PKC isoforms. Recent advances in targeting PKC isoforms have come from structural work on isolated kinase domains that have provided opportunities to drive selectivity through structure-based avenues. The promise of isoform selective inhibitors and the rationale for their development are discussed in the broader context of the PKC inhibitor arsenal.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cell Biology
Authors
Jon Roffey, Carine Rosse, Mark Linch, Andrew Hibbert, Neil Q McDonald, Peter J Parker,